Finding effective treatments for cancer remains a challenge. Recent studies have found that
the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal …

Chemotherapy, surgery, and radiation are accepted as the preferred treatment modalities
against cancer, but in recent years the use of immunotherapeutic approaches has gained …

Background Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the
first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated …

Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs
placebo in patients with advanced gastric cancer treated with≥ 2 chemotherapy regimens …

Objective V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint
protein that belongs to the B7 family. The aim of this study was to investigate the prognostic …

Importance Although quality of life (QOL) is an important clinical end point, cancer drugs are
often approved based on overall survival (OS) or putative surrogate end points such as …

Purpose Anticancer agents are known to increase cancer-associated thrombosis (CAT)
onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel …

The past 30 years have borne witness to a gradual evolution in the treatment landscape of
advanced renal cell carcinoma (aRCC). Early immunotherapy approaches such as …

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …

Background The efficacy and safety of nivolumab versus chemotherapy was evaluated in
the Japanese subpopulation from the overall intent-to-treat (ITT) population of the …